Sirius XM Holdings Inc vs Twist Bioscience Corp — how do they compare? Sirius XM Holdings Inc trades at $28.27 (market cap $9.70B), while Twist Bioscience Corp trades at $123.65 (market cap $7.72B). The key difference: Sirius XM Holdings Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SIRI | TWST | |
|---|---|---|
Market Cap | $9.70B | $7.72B |
Sector | Media | Health |
52-Week High | $32.59 | $124.88 |
52-Week Low | $19.92 | $24.16 |
Enterprise Value | $18.98B | $7.65B |
Dividend Yield | 3.75% | — |
Signals from Pluang's Aura AI — not financial advice
SIRI trades at $28.78, down 3.78% today, reflecting a bearish technical signal amid mixed earnings. The stock shows modest revenue growth and strong cash flow, with a P/E of 11.56 and P/B of 0.81 indicating potential undervaluation. Recent Q2 2026 earnings missed estimates, but the company raised full-year guidance, highlighting stable subscriber metrics and a dividend payout.
The outlook is cautiously optimistic, supported by analyst consensus of $33.17 price target and 58% buy ratings. Key risks include competitive pressures in satellite radio and high debt levels, though declining leverage and share buybacks offer upside. Investors should weigh stable cash generation against growth challenges.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Trailing returns across standard periods
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →